TXR-1210

TXR-1210 is a preclinical **small molecule** drug candidate discovered by **twoXAR Pharmaceuticals** and later associated with **Aria Pharmaceuticals** for the treatment of **chronic kidney disease**. It is described as a novel anti-inflammatory and anti-fibrotic program designed to **inhibit pyroptosis** and **regulate interleukin-1 activity**, with downstream effects including reduced release of proinflammatory cytokines and inhibition of **transforming growth factor beta** expression. In a unilateral ureteral obstruction mouse model, TXR-1210 reportedly reduced renal fibrosis and inflammation, including decreases in myofibroblast activation and infiltrating T cells, and was described as well tolerated. The candidate was identified using the company's AI-driven drug discovery platform.